The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts

Antonio T. Baines, Hanna Holubec, Jenny L. Basye, Patricia Thorne, Achyut K Bhattacharyya, Julian Spallholz, Brent Shriver, Haiyan Cui, Denise Roe, Larry C. Clark, David L. Earnest, Mark A Nelson

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

We evaluated the effects of dietary selenomethionine supplementation on colonic polyamine levels and the ability of l-selenomethionine supplementation to modulate the carcinogenic activity of azoxymethane (AOM) in the rat colon. Four-week-old male F344 rats were treated with 15 mg/kg body weight of AOM once a week for 2 weeks. Dietary selenomethionine at a concentration of either 1 or 2 ppm was administered in AIN-76A rodent diet to AOM-treated animals for 16 weeks. Aberrant crypt foci (ACF), precursor lesions of colon cancer, were investigated after the 16 week treatment course. Selenomethionine given in the diet at 2 ppm markedly reduced the number of aberrant crypt foci. The multiplicity of ACFs (i.e. the number of aberrant crypts/focus) and the percentage of microadenomas were also affected by selenomethionine in a dose dependent manner. However, evaluation of the colonic tissue polyamine levels between control and treated groups showed no significant difference. These results demonstrate that selenomethionine can modulate the development of AOM-induced premalignant lesions through a polyamine-independent mechanism. (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)193-198
Number of pages6
JournalCancer Letters
Volume160
Issue number2
DOIs
StatePublished - Nov 28 2000

Fingerprint

Azoxymethane
Selenomethionine
Polyamines
Aberrant Crypt Foci
Diet
Inbred F344 Rats
Dietary Supplements
Colonic Neoplasms
Rodentia
Colon
Body Weight
Control Groups

Keywords

  • Abberant crypts
  • Cancer prevention
  • Selenomethionine

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts. / Baines, Antonio T.; Holubec, Hanna; Basye, Jenny L.; Thorne, Patricia; Bhattacharyya, Achyut K; Spallholz, Julian; Shriver, Brent; Cui, Haiyan; Roe, Denise; Clark, Larry C.; Earnest, David L.; Nelson, Mark A.

In: Cancer Letters, Vol. 160, No. 2, 28.11.2000, p. 193-198.

Research output: Contribution to journalArticle

Baines, AT, Holubec, H, Basye, JL, Thorne, P, Bhattacharyya, AK, Spallholz, J, Shriver, B, Cui, H, Roe, D, Clark, LC, Earnest, DL & Nelson, MA 2000, 'The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts', Cancer Letters, vol. 160, no. 2, pp. 193-198. https://doi.org/10.1016/S0304-3835(00)00585-1
Baines, Antonio T. ; Holubec, Hanna ; Basye, Jenny L. ; Thorne, Patricia ; Bhattacharyya, Achyut K ; Spallholz, Julian ; Shriver, Brent ; Cui, Haiyan ; Roe, Denise ; Clark, Larry C. ; Earnest, David L. ; Nelson, Mark A. / The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts. In: Cancer Letters. 2000 ; Vol. 160, No. 2. pp. 193-198.
@article{48f235bd38334c8fad03d550a3c427e4,
title = "The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts",
abstract = "We evaluated the effects of dietary selenomethionine supplementation on colonic polyamine levels and the ability of l-selenomethionine supplementation to modulate the carcinogenic activity of azoxymethane (AOM) in the rat colon. Four-week-old male F344 rats were treated with 15 mg/kg body weight of AOM once a week for 2 weeks. Dietary selenomethionine at a concentration of either 1 or 2 ppm was administered in AIN-76A rodent diet to AOM-treated animals for 16 weeks. Aberrant crypt foci (ACF), precursor lesions of colon cancer, were investigated after the 16 week treatment course. Selenomethionine given in the diet at 2 ppm markedly reduced the number of aberrant crypt foci. The multiplicity of ACFs (i.e. the number of aberrant crypts/focus) and the percentage of microadenomas were also affected by selenomethionine in a dose dependent manner. However, evaluation of the colonic tissue polyamine levels between control and treated groups showed no significant difference. These results demonstrate that selenomethionine can modulate the development of AOM-induced premalignant lesions through a polyamine-independent mechanism. (C) 2000 Elsevier Science Ireland Ltd.",
keywords = "Abberant crypts, Cancer prevention, Selenomethionine",
author = "Baines, {Antonio T.} and Hanna Holubec and Basye, {Jenny L.} and Patricia Thorne and Bhattacharyya, {Achyut K} and Julian Spallholz and Brent Shriver and Haiyan Cui and Denise Roe and Clark, {Larry C.} and Earnest, {David L.} and Nelson, {Mark A}",
year = "2000",
month = "11",
day = "28",
doi = "10.1016/S0304-3835(00)00585-1",
language = "English (US)",
volume = "160",
pages = "193--198",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts

AU - Baines, Antonio T.

AU - Holubec, Hanna

AU - Basye, Jenny L.

AU - Thorne, Patricia

AU - Bhattacharyya, Achyut K

AU - Spallholz, Julian

AU - Shriver, Brent

AU - Cui, Haiyan

AU - Roe, Denise

AU - Clark, Larry C.

AU - Earnest, David L.

AU - Nelson, Mark A

PY - 2000/11/28

Y1 - 2000/11/28

N2 - We evaluated the effects of dietary selenomethionine supplementation on colonic polyamine levels and the ability of l-selenomethionine supplementation to modulate the carcinogenic activity of azoxymethane (AOM) in the rat colon. Four-week-old male F344 rats were treated with 15 mg/kg body weight of AOM once a week for 2 weeks. Dietary selenomethionine at a concentration of either 1 or 2 ppm was administered in AIN-76A rodent diet to AOM-treated animals for 16 weeks. Aberrant crypt foci (ACF), precursor lesions of colon cancer, were investigated after the 16 week treatment course. Selenomethionine given in the diet at 2 ppm markedly reduced the number of aberrant crypt foci. The multiplicity of ACFs (i.e. the number of aberrant crypts/focus) and the percentage of microadenomas were also affected by selenomethionine in a dose dependent manner. However, evaluation of the colonic tissue polyamine levels between control and treated groups showed no significant difference. These results demonstrate that selenomethionine can modulate the development of AOM-induced premalignant lesions through a polyamine-independent mechanism. (C) 2000 Elsevier Science Ireland Ltd.

AB - We evaluated the effects of dietary selenomethionine supplementation on colonic polyamine levels and the ability of l-selenomethionine supplementation to modulate the carcinogenic activity of azoxymethane (AOM) in the rat colon. Four-week-old male F344 rats were treated with 15 mg/kg body weight of AOM once a week for 2 weeks. Dietary selenomethionine at a concentration of either 1 or 2 ppm was administered in AIN-76A rodent diet to AOM-treated animals for 16 weeks. Aberrant crypt foci (ACF), precursor lesions of colon cancer, were investigated after the 16 week treatment course. Selenomethionine given in the diet at 2 ppm markedly reduced the number of aberrant crypt foci. The multiplicity of ACFs (i.e. the number of aberrant crypts/focus) and the percentage of microadenomas were also affected by selenomethionine in a dose dependent manner. However, evaluation of the colonic tissue polyamine levels between control and treated groups showed no significant difference. These results demonstrate that selenomethionine can modulate the development of AOM-induced premalignant lesions through a polyamine-independent mechanism. (C) 2000 Elsevier Science Ireland Ltd.

KW - Abberant crypts

KW - Cancer prevention

KW - Selenomethionine

UR - http://www.scopus.com/inward/record.url?scp=0034727780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034727780&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(00)00585-1

DO - 10.1016/S0304-3835(00)00585-1

M3 - Article

C2 - 11053649

AN - SCOPUS:0034727780

VL - 160

SP - 193

EP - 198

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -